Ratings Cogstate Limited

Equities

CGS

AU000000CGS8

Market Closed - Australian S.E. Other stock markets 02:10:31 2024-05-06 am EDT			5-day change	1st Jan Change
1.4 ^AUD	0.00%		+2.19%	-3.11%

Apr. 01	Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment	MT
Feb. 22	Cogstate's Fiscal H1 Attributable Profit Jumps, Revenue Rises 3%; Shares Decline 8%	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 45.8 times its estimated earnings per share for the ongoing year.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
COGSTATE LIMITED	-3.11%	158M	-
MODERNA, INC.	+22.81%	47.9B	B-
LONZA GROUP AG	+46.56%	41.42B	A
IQVIA HOLDINGS INC.	-1.88%	40.7B	B
CELLTRION, INC.	-6.20%	28.92B	C
ICON PUBLIC LIMITED COMPANY	+11.33%	25.55B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.27B	B
BIO-TECHNE CORPORATION	-1.43%	12.15B	B+
MEDPACE HOLDINGS, INC.	+30.73%	12.14B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.48%	11.99B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes